The EANM guideline for radiosynoviorthesis

Area of Science:

• Nuclear medicine
• Rheumatology
• Radiopharmacology

Background:

• Radiosynoviorthesis (RSO) is a long-standing intraarticular treatment for inflammatory joint diseases.
• Beta-particle emitting radiocolloids are phagocytized by synovial macrophages, causing tissue sclerosis and fibrosis.
• This process leads to reduced joint effusion and pain alleviation.

Purpose of the Study:

• To provide guidelines for nuclear medicine physicians performing radiosynoviorthesis.
• To address clinical, procedural, legislative, dosimetric, and safety aspects of RSO.
• To offer a framework for individualized RSO protocols across European countries.

Main Methods:

• Guidelines developed by the European Association of Nuclear Medicine (EANM) in collaboration with international clinical experts, including rheumatologists.
• Comprehensive review of radiopharmaceuticals, indications, procedural techniques, and patient management.
• Consideration of national legislative variations and potential complications.

Main Results:

• Established a framework for performing radiosynoviorthesis.
• Detailed considerations for radiopharmaceutical selection and application.
• Addressed potential side effects and complications associated with RSO.

Conclusions:

• These guidelines aim to assist nuclear medicine physicians in the safe and effective application of radiosynoviorthesis.
• Recognizes variations in approved radiopharmaceuticals and indications across European countries.
• Emphasizes the need for individual adoption of the guideline framework.